Lawrence Erik Kurzius Buys 10,000 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average price of $10.90 per share, with a total value of $109,000.00. Following the completion of the acquisition, the director now directly owns 101,459 shares of the company’s stock, valued at $1,105,903.10. This trade represents a 10.93 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Tuesday, March 11th, Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock. The stock was bought at an average price of $10.20 per share, with a total value of $102,000.00.

Elanco Animal Health Trading Down 6.8 %

Shares of Elanco Animal Health stock opened at $10.07 on Wednesday. Elanco Animal Health Incorporated has a 52-week low of $10.03 and a 52-week high of $18.80. The stock’s 50-day simple moving average is $11.56 and its 200 day simple moving average is $12.83. The stock has a market capitalization of $4.98 billion, a P/E ratio of 25.16, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business earned $0.08 EPS. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in Elanco Animal Health by 1,153.6% during the fourth quarter. FMR LLC now owns 40,232,327 shares of the company’s stock worth $487,213,000 after purchasing an additional 37,022,891 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Elanco Animal Health by 76.6% during the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. Norges Bank bought a new stake in Elanco Animal Health during the fourth quarter worth about $47,424,000. Brandes Investment Partners LP lifted its stake in Elanco Animal Health by 66.9% during the fourth quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock worth $69,405,000 after purchasing an additional 2,296,691 shares during the last quarter. Finally, Freestone Grove Partners LP bought a new stake in Elanco Animal Health during the fourth quarter worth about $20,396,000. 97.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Stifel Nicolaus decreased their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. UBS Group decreased their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.